Hillel Cohen, PhD, on How to Avoid Confusion in Biosimilar Promotions
September 22nd 2020Hillel Cohen, PhD, Education Committee co-chair for the Biosimilars Forum and executive director of Scientific Affairs for Sandoz, discussed whether disclosure statements are needed for biosimilar products and what they should contain, according to the biosimilar industry perspective.
Part 2: Wayne Winegarden, PhD, on What Canada Can Teach the United States About Biosimilars
September 17th 2020Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation, discussed why importing drugs may not lower costs and what we can learn from Canada’s biosimilar programs.
Part 1: Wayne Winegarden, PhD, on How Employers Can Better Manage Their Formularies
September 15th 2020Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation, discussed where the biosimilar market is heading and how employers can incentivize biosimilar utilization.
Part 2: Brian Gifford on How Treatment Adherence Can Help Employers Save
September 10th 2020Brian Gifford, research director of the Integrated Benefits Institute (IBI), discussed how employers can improve treatment adherence for their employees with rheumatic conditions in order to keep them productive and on the job.
Part 1: Brian Gifford on the Hidden Costs of Rheumatoid Arthritis
September 8th 2020Brian Gifford, research director of the Integrated Benefits Institute (IBI), discussed employer challenges with managing expenses associated with rheumatoid arthritis and how skillful management of rheumatoid arthritis can keep employees on the job and reduce expense.
Part 2: Surya Singh, MD, on Whether Biosimilars Will Lower Drug Costs
September 3rd 2020Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed the future for the US adalimumab market and whether biosimilars can deliver on the promise of lower cost health care.
Part 1: Surya Singh, MD, on Biosimilar Rebates and Payer Decisions
September 2nd 2020Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed how payers’ decisions regarding formulary lists affect patient out-of-pocket costs and access to biosimilars.
Part 2: Cheryl Larson on What Employers Can Do to Influence Health Plan Decisions
August 27th 2020Cheryl Larson, president and CEO of the Midwest Business Group on Health, based in Chicago, Illinois, discussed what employers can do to get biosimilars added to their formulary lists and ensure their pharmacy benefit managers (PBMs) aren’t taking advantage of them.
Part 1: Cheryl Larson on How Employers Are Taking on PBMs
August 25th 2020Cheryl Larson, president and CEO of Midwest Business Group on Health, based in Chicago, Illinois, discussed how some employers are taking on pharmacy benefit managers (PBMs) to get biosimilars added to their formularies and what it could mean for biosimilar savings going forward.
Part 2: Swaminathan P. Iyer, MD, Discusses Changing the Infrastructure of Drug Access
August 20th 2020Swaminathan P. Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discussed oncology biologics that are too costly for patients whether the Doha Declaration, which would enable governments to license the manufacture of these products, is a viable option.
Part 1: Swaminathan P. Iyer, MD, Discusses Need for Biosimilars in India, US
August 18th 2020Swaminathan Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, discussed the importance of biosimilars in India and the United States and the main concerns originator companies have regarding biosimilar competition.
Part 2: Nancy Globus on Whether or Not Biosimilar Naming Causes Confusion
August 13th 2020Nancy J. Globus, PharmD, vice president of Regulatory Affairs at the Accreditation Council for Medical Affairs (ACMA), discusses the truth behind 4-letter suffixes and product confusion among physicians and pharmacists.
Part 2: Axinn Patent Attorneys Discuss New Challenges for Insulins Under the BPCIA
July 23rd 2020Ted Mathias and Stacie Ropka, PhD, intellectual property law partners with Axinn, Veltrop and Harkrider LLP, discuss patent disputes and interchangeability designations with regard to insulin products under the Biologics Price Competition and Innovation Act (BPCIA). This is Part 2 of the interview. To watch Part 1, click here.
Rathore Discusses Study on Biosimilar Application Failures
July 22nd 2020The Center for Biosimilars® interviewed Anurag S. Rathore, PhD, whose team of investigators evaluated why applications for biosimilar approvals do not succeed. Large companies as well as small find the approval process challenging, but there is a learning curve that may be followed by more consistent approvals, he explains.
Part 1: Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21st 2020Ted Mathias and Stacie Ropka, PhD, intellectual property law partners with Axinn Veltrop and Harkrider LLP, met with The Center for Biosimilars® to discuss how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act, as well as the new challenges follow-on manufacturers will face.
Celltrion: Infliximab Biosimilar Shows Promise for COVID-19
July 14th 2020Byoungseo Choi, head of marketing for Celltrion Healthcare, discusses how Celltrion's infliximab biosimilar can aid in the treatment of coronavirus disease 2019 (COVID-19)–related inflammation, as well as the company’s launch plans for biosimilars through 2030.
Kathy Oubre: Other Players Complicate Biosimilar Use for Cancer Centers
July 2nd 2020Kathy Oubre, chief operating officer at the Pontchartrain Cancer Center in Louisiana, president of the Louisiana Medical Group Management Association and member of the board of directors for the Community Oncology Alliance, discusses how payers, pharmacy benefit managers, and manufacturers make providing biosimilars complicated for patients and providers.
Ryan Haumschild, PharmD, Outlines Ways to Boost Physician Confidence in Biosimilars
July 1st 2020Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare in Atlanta, Georgia, discussed results to the survey he conducted on biosimilar utilization and planned initiatives about how to increase physician confidence in biosimilars.
Part 2: Nick Mitrokostas on the Race for the First Interchangeable Biosimilar
June 24th 2020Nick Mitrokostas, an intellectual property law attorney with Goodwin Proctor in Boston and editor-in-chief of Big Molecule Watch, discussed the building anticipation for the first interchangeable biosimilar and whether the FDA is doing enough to facilitate the development of more biosimilars and quell anticompetitive practices.
Part 1: Nick Mitrokostas on How COVID-19, FDA Rule Changes Are Shaping the Biosimilar Market
June 23rd 2020Nick Mitrokostas, an intellectual property law attorney with Goodwin Proctor in Boston and editor in chief of Big Molecule Watch, discussed the impact on the US biosimilar market from the coronavirus disease 2019 (COVID-19) pandemic and the recent change to the Biologics Price Competition and Innovation Act (BPCIA).
Part 2: Christine Simmon Discusses Payer Influence on Provider Behavior
June 18th 2020Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) discussed the new pathway for insulin biosimilars and the struggles between payers and providers over biosimilar choice.
Part 1: Christine Simmon Discusses the Individual Mandate and Biosimilars
June 16th 2020Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) discusses potential legislation that the AAM is advocating for and how the upcoming election and Supreme Court decision will affect biosimilars.
Joseph Fuhr, PhD, Discusses Competition for the Growing Biosimilar Market
June 10th 2020Joseph P. Fuhr Jr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics discusses how future biosimilar competition will affect consumers and market development.
Ha Kung Wong and April Breyer Menon Discuss Promising and Not-so-Promising Biosimilar Legislation
June 5th 2020An extended interview with Ha Kung Wong, JD, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, JD, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago discussing potential biosimilars legislation.
Part 2: Ali McBride Discusses Initiatives to Improve Physician Education on Biosimilars
May 25th 2020Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses physician struggles tied to biosimilar utilization, the upcoming initiatives for the ACCC Biosimilars Center, and why physicians should be keeping an eye on biosimilars.
Part 1: Ali McBride Discusses ACCC Initiatives and Biosimilar Uptake
May 18th 2020Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses the anticipated growth for the US biosimilar market and what the ACCC is doing to further uptake efforts.